A multi-centre, Australian and New Zealand, phase II exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (ANZHIT-2) (ACTRN12622001232729)

This study (ANZHIT-2) aims to improve the treatment protocols in haploidentical (half match) transplants. We will be using more targeted chemotherapy and total body irradiation in the transplants thus improving on their safety and success. We will also compare the cost-effectiveness and quality of life of haploidentical transplants to matched donor transplants.

Trial phase

Phase 2

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof David Curtis

Key inclusion data

Key Inclusion: Recipients must have a haematological malignancy with a significant risk of relapse where allogeneic transplant is indicated; Adults without a matched related or unrelated donor or where the time for the donor cells to arrive places the patient at a high risk of relapse; Patients must have a first-degree relative who are 3/6 to 4/6 HLA matched (i.e. haploidentical); Adequate cardiac, pulmonary and renal function. Key Exclusion: Pregnancy; Positive serology for HIV; Refractory Central Nervous System (CNS) disease; Refractory lymphoma.